ArticleOphthalmology and therapy2026
Intravitreal Dexamethasone Implant in Punctate Inner Choroidopathy: Clinical Indications and Outcomes in a Real-World Case Series.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study is to characterize the clinical indications, treatment patterns, and outcomes associated with intravitreal dexamethasone implant (DEX implant) in eyes with punctate inner choroidopathy (PIC).
methodsThis retrospective observational case series included eyes with PIC treated with at least one DEX implant. Eyes were categorized according to the indication for treatment as (1) bridging therapy while initiating systemic immunomodulatory therapy (IMT), (2) adjunctive treatment for recurrent inflammatory activity despite ongoing IMT, or (3) local therapy in patients not receiving systemic IMT. Main outcome measures included best-corrected visual acuity (BCVA), inflammatory control, inflammatory recurrence, retreatment requirements, and safety.
resultsTwenty-five eyes from 22 patients were included. Mean age at index injection was 56.5 ± 11.1 years, and 18/22 patients (82%) were female. DEX implant was used as bridging therapy in 5 eyes (20%), adjunctive therapy during ongoing IMT in 6 eyes (24%), and local therapy without IMT in 14 eyes (56%). A total of 33 DEX implants were administered during follow-up. Complete resolution of inflammatory activity was achieved in all eyes within 6 months of the first DEX implant. Mean BCVA remained stable, from 0.33 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.34 logMAR at month 6. Inflammatory recurrence occurred in 7/25 eyes (28%) after a mean of 6.0 ± 3.5 months, with no recurrences observed among eyes receiving DEX implant during ongoing IMT. Intraocular pressure elevation occurred in 12/25 eyes (48%) and was successfully controlled with topical therapy. Other ocular adverse events were infrequent and included retinal detachment, peripheral retinal hole, hypotony, and posterior vitreous detachment, each occurring once in a different eye (4% each).
conclusionsIntravitreal DEX implant provides effective short-term control of inflammatory activity in PIC and serves multiple complementary roles in clinical practice, including bridging during IMT initiation, adjunctive treatment for breakthrough inflammation, and stand-alone local therapy in selected patients. The absence of recurrences among eyes receiving concomitant IMT and the higher recurrence rate in those cases managed without systemic immunomodulation suggest that DEX implant is most effectively integrated into a broader long-term immunomodulatory strategy for patients with relapsing disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.